Jay T. Backstrom
CIK 1796398 · CHIEF EXECUTIVE OFFICER · last filed 2026-07-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$21.06M
Companies
4
Total Filings
18
Lifetime Open-Market Net
-$1.85M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AGIO | Director | 1,447 | $35.99 | $52.1K | $0 | 3 | 2026-07-10 |
| LAVA Therapeutics NV (LVTX) Delisted | Director | — | $1.74 | — | $0 | 2 | 2025-11-17 |
| SRRK | CHIEF EXECUTIVE OFFICER | 425,561 | $49.37 | $21.01M | -$1.85M | 7 | 2025-03-12 |
| ACCELERON PHARMA INC (XLRN) Delisted | EVP, Research and Development | 0 | $178.75 | $0 | $0 | 5 | 2021-11-22 |
Recent Filings · Page 2 of 2
18 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-02-15 | SRRK | Grant (A) | +150,000 | $0 | EDGAR |
| 2023-01-03 | — | Grant (A) | — | $0 | |
| 2022-09-22 | SRRK | Grant (A) | — | $0 | EDGAR |
| 2021-11-22 | ACCELERON PHARMA INC (XLRN) Delisted | Mixed | −21,233 | $0 | EDGAR |
| 2021-02-02 | ACCELERON PHARMA INC (XLRN) Delisted | Grant (A) | +5,409 | $0 | EDGAR |
| 2021-01-06 | ACCELERON PHARMA INC (XLRN) Delisted | Tax (F) | −1,735 | -$215.7K | EDGAR |
| 2020-02-10 | ACCELERON PHARMA INC (XLRN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-01-03 | ACCELERON PHARMA INC (XLRN) Delisted | Grant (A) | +17,107 | $0 | EDGAR |
Showing 11–18 of 18
Prev
Page 2 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.